StreetAlpha.app
Home › Stocks › MPLT

MapLight Therapeutics, Inc. (MPLT)

Healthcare
$6.57
▼ −4.78%
LAST CLOSE · NOV 17

MapLight Therapeutics develops treatments for central nervous system disorders, with candidates in clinical trials for schizophrenia and autism. It last closed at $6.57 on Nov 17, down 4.78% on the day. MPLT last reported earnings on Fri, Sep 18, 2026. The average 12-month price target from 2 analysts is $32.00 (+387.1% from the last close), with a high of $43.00 and a low of $21.00.

AI Auto Pilots
Is MPLT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$252.0M
EPS (diluted)
$83.54
Free cash flow
−$179.0M
Balance sheet
Cash & equivalents
$55.6M
At Sep 30
Shareholder equity
$445.8M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: −$77.6M−$77.6MFY2024FY2025: −$161.2M−$161.2MFY2025

From MPLT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Sep 18
2026 · Time not announced
Reported EPS
-$1.32
vs -$1.35 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated MPLT in the past 90 days, not enough for a consensus
Average 12-month target
$32.00
▲ 387.1% upside

Based on 2 analysts who set a price target on MPLT in the past 90 days. The average target is $32.00, with a high of $43.00 and a low of $21.00, compared with the last close of $6.57.

Low $21.00Avg $32.00High $43.00
Blue marker: last close $6.57
Highest target$43.00
Average target$32.00
Lowest target$21.00
Latest rating changes
Canaccord GenuityTarget lowered
Nov 17Buy$24 → $21
NeedhamTarget lowered
Aug 31Buy$45 → $43
UBSDowngrade
Aug 10Hold$52 → $13
Canaccord GenuityTarget lowered
Jul 28Buy$43 → $24
Morgan StanleyDowngrade
Jul 28Hold$21
DateFirmActionRatingPrice target
Nov 17Canaccord GenuityTarget loweredBuy$24 → $21
Aug 31NeedhamTarget loweredBuy$45 → $43
Aug 10UBSDowngradeHold$52 → $13
Jul 28Canaccord GenuityTarget loweredBuy$43 → $24
Jul 28Morgan StanleyDowngradeHold$21
Loading…

Technical Analysis

MPLT · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 12% below its 20 day and 38% below its 50 day average. It is 202% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 35), near oversold. The nearest support is the Pivot S1 at $6.36, and the nearest resistance the Pivot at $6.63.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 9.1%/day
Key levels
$40.4352 week high+515.4%
$19.85200 day average+202.1%
$15.40100 day average+134.4%
$9.0650 day average+37.9%
$7.80Swing high (Nov 11)+18.7%
$7.3520 day average+11.9%
$6.85Pivot R1+4.3%
$6.63Pivot+0.9%
$6.57Last close
$6.36Pivot S1−3.2%
$6.0652 week low−7.8%
$6.06Swing low (Nov 6)−7.8%
Indicators
RSI (14)34.57Weak, oversold below 30Neutral
MACD-0.62Above its signal lineBullish
Stochastic39.2Middle of its rangeNeutral
ADX (14)45.7Strong downtrend
Williams %R-76.1Oversold below −80, overbought above −20Neutral
CCI (20)-106.4Oversold below −100, overbought above 100Oversold
Rate of change−3.5%Change over 10 sessionsBearish
ATR (14)$0.60Typical daily range, 9.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MPLT

What happened before

See how MPLT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in MPLT in the last 90 days.

Loading…

See today’s whale options flow across the market →

MPLT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●59 buying vs 54 selling
  • ▲Held by funds +11.5 pts
  • ▼Funds holding -9
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding98107−8.4%
In funds' top 1038−62.5%
Held by funds73.3%61.9%+11.5 pts
New / increased20 / 3937 / 21+1.7%
Reduced / sold out27 / 2729 / 10+38.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MPLT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MPLT is in one of them and how their past MPLT trades turned out.

MPLT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MPLT in an article yet. Here's the latest on the wider market.

About MapLight Therapeutics

MapLight Therapeutics is a biopharmaceutical company based in Redwood City, California, that develops medicines for disorders of the central nervous system. Its main candidate, ML-007C-MA, is in clinical trials for schizophrenia and for psychosis linked to Alzheimer's disease. The company is also testing ML-004 for social communication difficulties in autism and has several preclinical programs. Its treatments are aimed at patients and the prescribers who care for them.

Headquarters
Redwood City, CA